Bylvay
Drug
ALBIREO PHARMA, INC.
Total Payments
$7.4M
Transactions
5,507
Doctors
2,205
Companies
3
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $2.7M | 3,166 | 1,726 |
| 2023 | $2.7M | 1,613 | 592 |
| 2022 | $2.1M | 728 | 217 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $5.5M | 1,217 | 74.6% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $818,427 | 201 | 11.0% |
| Consulting Fee | $706,933 | 212 | 9.5% |
| Travel and Lodging | $163,179 | 283 | 2.2% |
| Food and Beverage | $117,738 | 3,517 | 1.6% |
| Space rental or facility fees (teaching hospital only) | $51,350 | 16 | 0.7% |
| Honoraria | $21,878 | 8 | 0.3% |
| Education | $601.71 | 53 | 0.0% |
Payments by Type
Research
$5.5M
1,217 transactions
General
$1.9M
4,290 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Odevixibat (A4250) in Children With Biliary Atresia Who Have Undergone a Kasai Hepatoportoenterostomy | ALBIREO PHARMA, INC. | $2.8M | 1 |
| An Open-label Extension Study to Evaluate Long-term Efficacy and Safety of Odevixibat (A4250) in Children with Biliary Atresia (BOLD-EXT) | ALBIREO PHARMA, INC. | $1.3M | 2 |
| An Open Label Study to Evaluate the Long-term Safety and Efficacy of Odevixibat (A4250) in Patients With Alagille Syndrome (ASSERT-EXT) | ALBIREO PHARMA, INC. | $625,339 | 0 |
| Odevixibat (A4250) for the Treatment of Progressive Familial Intrahepatic Cholestasis (Expanded Access Program) | ALBIREO PHARMA, INC. | $426,724 | 1 |
| A Phase 3 Double-blind, Randomized, Placebo-controlled Study of the Safety and Efficacy of Odevixibat (A4250) in Patients With Alagille Syndrome (ASSERT) | ALBIREO PHARMA, INC. | $364,897 | 0 |
| An Open-label Extension Study to Evaluate Long-term Efficacy and Safety of A4250 in Children With Progressive Familial Intrahepatic Cholestasis Types 1 and 2 (PEDFIC 2) | ALBIREO PHARMA, INC. | $59,120 | 1 |
Top Doctors Receiving Payments for Bylvay — Page 3
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| , FNP | Nurse Practitioner | Glendale, AZ | $7,208 | 11 |
| , M.D | Pediatrics | San Diego, CA | $7,195 | 5 |
| , M.D | Pediatrics | San Francisco, CA | $7,138 | 5 |
| , MBBS, MS | Pediatric Gastroenterology | Los Angeles, CA | $7,083 | 4 |
| , MD | Pediatric Gastroenterology | Louisville, KY | $6,821 | 1 |
| , MD | Family Medicine | Montgomery, AL | $6,815 | 5 |
| , MD | Pediatric Gastroenterology | Atlanta, GA | $6,570 | 2 |
| Jessica Michael | Family | Cincinnati, OH | $6,250 | 5 |
| , MD | Pediatric Gastroenterology | New Haven, CT | $6,058 | 4 |
| , MD | Pediatric Gastroenterology | Milwaukee, WI | $5,984 | 3 |
| , MD | Pediatric Gastroenterology | Bronx, NY | $5,847 | 7 |
| , MD | Hepatology | New York, NY | $5,773 | 2 |
| , M.D | Gastroenterology | Houston, TX | $5,541 | 7 |
| , M.D | Pediatric Gastroenterology | Cleveland, OH | $5,521 | 5 |
| , M.D | Pediatrics | Philadelphia, PA | $5,478 | 6 |
| , MD, PHD | Pediatric Gastroenterology | Atlanta, GA | $5,247 | 8 |
| , MD | Transplant Hepatology | Toms River, NJ | $5,216 | 6 |
| , M.D | Pediatrics | Hyden, KY | $5,106 | 8 |
| , MB CHB | Gastroenterology | Pittsburgh, PA | $4,875 | 5 |
| , MD | Hepatology | New York, NY | $4,550 | 1 |
| , M.D | Transplant Surgery | Rochester, NY | $4,530 | 2 |
| , M.D | Pediatrics | New York, NY | $4,244 | 2 |
| , NP | Pediatrics | New Hyde Park, NY | $4,143 | 5 |
| James Squires | Pediatric Gastroenterology | Pittsburgh, PA | $3,671 | 4 |
| , M.D | Internal Medicine | Kansas City, KS | $3,339 | 2 |
Ad
Manufacturing Companies
- ALBIREO PHARMA, INC. $6.5M
- Ipsen Biopharmaceuticals, Inc $874,030
- Ipsen Pharma SAS $452.80
Product Information
- Type Drug
- Total Payments $7.4M
- Total Doctors 2,205
- Transactions 5,507
About Bylvay
Bylvay is a drug associated with $7.4M in payments to 2,205 healthcare providers, recorded across 5,507 transactions in the CMS Open Payments database. The primary manufacturer is ALBIREO PHARMA, INC..
Payment data is available from 2022 to 2024. In 2024, $2.7M was paid across 3,166 transactions to 1,726 doctors.
The most common payment nature for Bylvay is "Unspecified" ($5.5M, 74.6% of total).
Bylvay is associated with 6 research studies, including "A Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Odevixibat (A4250) in Children With Biliary Atresia Who Have Undergone a Kasai Hepatoportoenterostomy" ($2.8M).